Ascentage Pharma Group Internat

AI-generated fair value estimate for this company.

Method: 10-year explicit-path FCF DCF: revenue grows from $94.6M at 40% tapering to 5% by yr10 as its approved drug (olverembatinib) and pipeline commercialize; FCF margin improves from -100% (yr1, heavy global trial spend) to a mature 25% by yr8-10; 13% discount rate; 3% terminal growth; $29.3M net debt; 373.25M shares outstanding.

Reasoning: Ascentage is a commercial-stage oncology biopharma with one approved product and a large late-stage pipeline including partnerships with Takeda, currently loss-making from heavy global R&D spend, so I modeled an explicit revenue-ramp and margin-normalization path toward typical specialty-oncology biopharma margins; the discount rate reflects clinical and regulatory risk across its pipeline.